ClinicalTrials.gg
CompletedNCT02500641FORWARDUpdated Jun 21, 2019Results posted

Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout

A Phase 4 interventional study of Febuxostat 80/120mg/day and Allopurinol 100 up to 600mg/day in Gout, sponsored by Menarini International Operations Luxembourg SA. Completed at 26 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-21.

Sponsored by Menarini International Operations Luxembourg SA (part of Menarini Group) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing febuxostat in Gout — 1 open to participants now, 1 under way, none of them phase 3. Febuxostat · Gout.

Enrollment
10th of 29
196 · median 109
Started
2015
with 1 other
Phase 4
6 of 29
1 open now
Registered
24th of 29
by date
Lead sponsor
1 of 29
Menarini International Operations Luxembourg SA

Among the 29 studies testing febuxostat in Gout, this one is the 10th largest by enrollment, is one of 2 that started in 2015, is one of 6 in phase 4, and was the 24th registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 29 studies testing febuxostat in Gout is open now. Recruiting first, the newest first:

About febuxostat

Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing febuxostat in Gout, or all of them as a file.
02

Study summary

There is a mounting and clear association between hyperuricaemia, gout and the presence of traditional cardiovascular (CV) risk factors and CV event-equivalent conditions such as chronic kidney disease, metabolic syndrome, and diabetes. Gout is associated with increased risk of CV events such as myocardial infarction and CV death. Furthermore hyperuricaemia is clearly associated with an increased arterial stiffness, a marker of pre-clinical atherosclerosis. Carotid-femoral pulse wave velocity (PWV) is the "gold standard" measurement of arterial stiffness and it is considered, in this trial, as a valid surrogate endpoint with clearly established relevance to predict cardiovascular disease (CVD) clinical outcome In this randomised trial conducted on adult subjects with a history of gout, we use surrogate endpoints to investigate the efficacy of febuxostat compared with allopurinol to predict (CVD) clinical outcome.

Eligible subjects were randomised in a 1:1 ratio to the following treatment groups:

  • Test product: febuxostat 80 mg or 120 mg once daily (120 mg daily, if serum urate was >6 mg/dL after 2 weeks of treatment at 80 mg daily).
  • Active comparator: allopurinol 100 mg once daily (up to a maximum dose of 600 mg daily escalated in 100 mg increments every 2 weeks, if serum urate acid (sUA) was >6 mg/dL after 2 weeks of treatment at the previous dose).

The study duration was 39 weeks, which included the:

  • Run-in/screening period: 1 week (extendable up to a maximum of 30 days according to variability of sUA levels);
  • Treatment period: 36 weeks;
  • Safety follow-up period: 2 weeks.
Read the detailed description

The study physician, responsible for randomization and drug supply handling, is unblinded to study medications and therefore will not be involved in the main efficacy evaluations of each patient randomized in the study.

Conversely, the study physician/s responsible for the main efficacy evaluation (Pulse Wave Velocity) will be blind to study treatments.

Key efficacy variables will be performed by an independent centralized laboratory.

Trial was conducted in a detailed and orderly manner in accordance with established research principles, International Conference on Harmonization (ICH), Good Clinical Practice (GCP) Guidelines and with Clinical Research Organization (CRO) Standard Operating Procedures (SOPs). As part of a concerted effort to fulfill these obligations, the authorised CRO study monitor visited investigative sites prior to and during the trial in addition to maintaining telephone and written communication. Data from each subject were reviewed and source verified as the study progressed.

In accordance with audit plans, this trial may have been selected for audits. The investigators committed to permit independent audits by auditors assigned by the Sponsor at a reasonable notice. Audits included, but were not limited to, drug supply, presence of required documents, the informed consent process, protection of rights and well-being of subjects and verification of Electronic case report form (eCRF) entries against source documents.

Regulatory authorities worldwide had the right to inspect the investigative sites during or after the trial. In such cases, the investigators were required to contact the Sponsor immediately and to fully cooperate with the inspectors.

Copies of written correspondence between the investigators, CRO, Sponsor, Competent Authorities, Institutional Review Board (IRB) and Independent Ethic Committee (IEC) are on file with the Sponsor and investigators.

Adverse events were according to the Medical Dictionary for Regulatory Activities (MedDRA, version 18.0) thesaurus.

Statistical analysis were conducted according the Statistical Analysis Plan (SAP) describing the analytical principles and statistical techniques employed in order to address the objectives specified in the Protocol.

A Data Management Plan was present for missing data, to address situations where variables are reported as missing, unavailable, non-reported, uninterpretable, or considered missing because of data inconsistency or out-of-range results.

03

Conditions studied

  • Gout

Keywords

  • Biological Markers
  • Cardiovascular disease
  • Humans
  • Pulse Wave Velocity
  • Cardiovascular risk factors
  • Allopurinol
  • Pulse Wave Analysis
  • Thiazoles
  • Inflammation
  • Uric acid
  • Febuxostat
  • Oxidative stress
  • Tumor Necrosis Factor
  • Arthritis
  • Hyperuricemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients 18 years and older;
  2. History of gout, flare free in the 4 weeks prior to study entry
  3. History of crystal (joint liquid) proven diagnosis or anamnestic diagnosis of gout according to Wallace at el. To be eligible, a subject had to present at least 6 of the following 12 clinical, laboratory, and x-ray phenomena:
  1. Maximum inflammation developed within 1 day, 2. More than one attack of acute arthritis, 3. Monoarticular arthritis attack, 4. Redness observed over joints, 5. First metatarsophalangeal (MTP) pain or swelling, 6. Unilateral first MTP joint attack, 7. Unilateral tarsal joint attack, 8. Suspected or proven tophus, 9. Hyperuricemia, 10. Asymmetric swelling within a joint on a X ray, 11. Subcortical cysts without erosions on X ray, 12. Negative organisms on culture of joint fluid; 4. Naive to ULT or previously treated with ULT, but with no ULT treatment in the last 1 month prior to study entry and only if reason for ULT interruption was not due to safety concerns.
  1. Patients at study entry have elevated serum urate level >8 mg/dl. 6. Overall Cardiovascular (CV) risk based on the scoring proposed by the Joint Task Force of the European Society of Cardiology and other European Societies on cardiovascular disease prevention in clinical practice between 5 and 15-% (inclusive). Patients with diabetes mellitus type 2 could be included in the study if their CV risk score is calculated as ≤7%.
  1. Allowed concomitant medications should be maintained stable during the last 2 weeks before randomisation

Exclusion criteria

Exclusion Criteria:

  1. Severe chronic renal failure ( \< 30 ml/min)
  2. Hepatic failure
  3. Active liver disease or hepatic dysfunction, defined as both (ALT) and aspartate aminotransferase (AST) >2 times the .
  4. Diabetes mellitus type1
  5. Life-threatening co-morbidity or with a significant medical condition and/or conditions that would interfere with the treatment, the safety or the compliance with the protocol
  6. Diagnosis of, or receiving treatment for (excluding basalioma skin cancer) in the previous 5 years
  7. Patients who have experienced either myocardial infarction or stroke
  8. Patients with inflammatory based arthritis (e.g.: rheumatoid arthritis, etc.)
  9. Patients with congestive heart failure, (NYHA) Class III or IV
  10. Patients with untreated/uncontrolled thyroid function
  11. Patients with clinically severe peripheral arterial disease
  12. Concomitant administration of any of the following: azathioprine, mercaptopurine, theophylline, meclofenamate, sulfinpyrazone, trimethoprim-sulfamethoxazole, cyclophosphamide, benzbromarone, pyrazinamide, captopril and enalapril (for Allopurinol), tegafur, pegloticase and tacrolimus.
  13. to any one of the active substances or to any of the
  14. Any to febuxostat or allopurinol (with reference to the summary of product characteristics).
  15. Subject is unable to take either of the protocol-required gout flare prophylactic medications (NSAID or colchicine) due to contraindications or intolerance, e.g. hypersensitivity, active gastric ulcer disease, renal impairment and/or changes in liver enzymes
  16. Participation in another trial of an drug or device within 30 days prior to screening, or prior treatment with investigational product(s)
  17. Women of (WOCBP), including peri-menopausal women who have had a menstrual period within 1 year, not willing to use highly effective method of throughout the study period and for 4 weeks after study completion defined as a method which results in a failure rate of less than 1% per year such as:

    • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal),
    • progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable),
    • intrauterine device (IUD),
    • intrauterine hormone-releasing system (IUS),
    • bilateral tubal occlusion,
    • vasectomised partner (provided that partner is the sole sexual partner of the trial participant and that the vasectomised partner has received medical assessment of the surgical success),
    • sexual abstinence;
  18. Severe psychiatric disorders/neurological disorders
  19. Severe concurrent pathology, including terminal illness (cancer, AIDS, etc)
  20. Abuse of alcohol, analgesics, or psychotropic drugs
  21. Inability or unwillingness, in the investigator's opinion, to follow study procedures including, but not limited to the ability to obtain adequate PWV/Pulse Wave Analysis (PWA) recordings. Special attention was made to any physical abnormalities which could affect quality of PWV/PWA measurement:

    • Neck region- neck flexibility and accessibility of carotid artery,
    • Upper arm and thigh region- exclude any abnormalities which would prevent adequate placement of the cuff;
  22. Inability or unwillingness to issue the
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
196 participants (actual)

Study arms

  • Experimental
    Febuxostat 80/120 mg/day

    Febuxostat 80/120 mg film coated tablets.The initial daily dose is 80 mg given orally. In case a patient has serum urate level 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained during the study treatment period. To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg quaque die (QD ) or in case of colchicine intolerance, Naproxen 550 mg bis in die (BID) with Omeprazole (20-40 mg once daily), if indicated to be used.

    Drug: Febuxostat 80/120mg/day · Drug: Colchicine · Drug: Naproxen · Drug: Omeprazole

  • Active comparator
    Allopurinol 100 up to 600 mg/day

    Allopurinol 100/300 mg tablets.The initial daily allopurinol dose is 100 mg given orally, to be escalated of 100 mg every 2 weeks in patients with serum urate concentration \>6 mg/dl. The maximum dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg daily.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD or in case of colchicine intolerance, Naproxen 550 mg BID with Omeprazole (20-40 mg once daily), if indicated to be used.

    Drug: Allopurinol 100 up to 600mg/day · Drug: Colchicine · Drug: Naproxen · Drug: Omeprazole

Interventions

  • DrugFebuxostat 80/120mg/day

    Drug page: Febuxostat

    Starting dose and dose regimen of Febuxostat : the initial daily dose is 80 mg. In case the patient has the serum urate concentration \> 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained for the duration of the study.

    Also known as: Adenuric

  • DrugAllopurinol 100 up to 600mg/day

    Drug page: Allopurinol

    Starting dose and dose regimen of allopurinol : the initial daily allopurinol dose is 100 mg, to be increased by 100 mg every 2 weeks in patients with serum urate concentration \>6 mg/dl. The maximum daily dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg.

    Also known as: Allopurinol

  • Colchicine 0.5 mg tablets.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD

  • Naproxen sodium 550 mg film coated tablets. In case of colchicine intolerance patients will be treated for at least 6 months with Naproxen 550 mg BID and Omeprazole (20-40 mg once daily), if indicated to be used.

    Also known as: Synflex

  • Omeprazole 20 mg capsules, co-administered to patients for gastric protection.

    Also known as: Omeprazen

06

What researchers measure

Primary outcomes

  1. Pulse Wave Velocity

    Comparison of the effects of Febuxostat and Allopurinol on Pulse Wave Velocity (PWV) after 36 weeks of treatment.

    Time frame: 36 weeks of treatment

07

Results

Posted Jun 21, 2019
Limitations and caveats
No limitations or caveats are applicable to this summary

Participant flow

Participant flow — Overall Study
MilestoneFebuxostat 80/120 mg/DayAllopurinol 100 up to 600 mg/Day
Started9898
Completed8886
Not completed1012
Withdrew: Adverse event02
Withdrew: Withdrawal by subject45
Withdrew: Unable to follow study procedures32
Withdrew: Protocol violation12
Withdrew: Lost to follow-up10
Withdrew: Sponsor decision10
Withdrew: Non compliance to study drug01

Outcome measures

PrimaryPulse Wave Velocity

Comparison of the effects of Febuxostat and Allopurinol on Pulse Wave Velocity (PWV) after 36 weeks of treatment.

Time frame:
36 weeks of treatment
Reported as:
Mean · m/s
Pulse Wave Velocity
m/sFebuxostat 80/120 mg/DayAllopurinol 100 up to 600 mg/Day
Pulse Wave Velocity9.0 ± 2.049.05 ± 1.99
Statistical analysis
  • Febuxostat 80/120 mg/Day vs Allopurinol 100 up to 600 mg/Day · ANCOVA · p = 0.5298

Adverse events

Collected over From signing of informed consent at visit -1 (from 7 to 30 days before treatment phase in case of retesting) to follow-up period of 2 weeks after the administration of the last treatment dose. Treatment duration was of 36 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Febuxostat 80/120 mg/Day0/98 (0%)10/98 (10.2%)50/98 (51%)
Allopurinol 100 up to 600 mg/Day0/98 (0%)8/98 (8.2%)61/98 (62.2%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventFebuxostat 80/120 mg/DayAllopurinol 100 up to 600 mg/Day
aortic aneurysmVascular disorders1/980/98
AdhesiolysisSurgical and medical procedures1/980/98
AppendicectomySurgical and medical procedures1/980/98
ColectomySurgical and medical procedures1/980/98
Coronary artery bypassSurgical and medical procedures1/980/98
Gastric bypassSurgical and medical procedures1/980/98
Large intestine operationSurgical and medical procedures1/980/98
Intraocular lens implantSurgical and medical procedures1/980/98
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/980/98
HypersensitivityImmune system disorders0/981/98
Most frequent other events
Showing 10 of 64
Most frequent other events
EventFebuxostat 80/120 mg/DayAllopurinol 100 up to 600 mg/Day
goutMetabolism and nutrition disorders10/9815/98
ArthralgiaMusculoskeletal and connective tissue disorders10/989/98
DiarrhoeaGastrointestinal disorders2/988/98
Upper respiratory tract infectionInfections and infestations1/987/98
Alanine aminotransferase increasedInvestigations4/981/98
Blood glucose increasedInvestigations3/984/98
Hepatic enzyme increasedInvestigations4/981/98
Abdominal pain upperGastrointestinal disorders0/984/98
Type 2 diabetes mellitusMetabolism and nutrition disorders0/984/98
HypertensionVascular disorders1/983/98

Baseline characteristics

All randomozed participants who had taken at least one dose of study drug specified by treatment group

Age, Categorical
Age, Categorical(Participants)Febuxostat 80/120 mg/DayAllopurinol 100 up to 600 mg/DayTotal
<=18 years000
Between 18 and 65 years6860128
>=65 years303868
Age, Continuous
Age, Continuous(years)Febuxostat 80/120 mg/DayAllopurinol 100 up to 600 mg/DayTotal
Mean58.66 ± 10.8360.52 ± 10.3559.59 ± 10.97
Sex: Female, Male
Sex: Female, Male(Participants)Febuxostat 80/120 mg/DayAllopurinol 100 up to 600 mg/DayTotal
Female171835
Male8180161
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Febuxostat 80/120 mg/DayAllopurinol 100 up to 600 mg/DayTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Febuxostat 80/120 mg/DayAllopurinol 100 up to 600 mg/DayTotal
Netherlands101
Romania272552
Poland385290
Italy9615
Serbia201232
Germany336
08

Study locations

26 sites
  • Medizinische Klinik und Poliklinik III/Rheumatologie Universitätsklinikum "Carl Gustav Carus" Der Technischen Universität
    Dresden, 01307, Germany
  • Presidio Ospedaliero San Filippo e Nicola Università degli Studi dell'Aquila U.O.C Geriatria e Lungodegenza Geriatrica
    Avezzano, L'Aquila 67051, Italy
  • Ospedale San Salvatore U.O.C. Medicina Interna e Nefrologia Dipartimento MeSVA Università degli Studi dell'Aquila
    Coppito, L'Aquila 67100, Italy
  • Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola-Malpighi
    Bologna, 40138, Italy
  • Ospedale Policlinico SS. Annunziata Università degli Studi "G. d'Annunzio". Dipartimento di Medicina e Scienze dell'Invecchiamento.
    Chieti, 66100, Italy
  • Reade Clinic
    Amsterdam, 1056, Netherlands
  • Gdańskie Centrum Zdrowia Sp.z o.o.
    Gdańsk, Poland
  • Specjalistyczna Praktyka Lekarska Piotr Kubalski
    Grudziądz, Poland
  • Centrum Medyczne Pratia Katowice
    Katowice, Poland
  • Centrum Medyczne Plejady
    Kraków, Poland
  • Krakowski Szpital Specjalistyczny im. Jana Pawła II w Krakowie
    Kraków, Poland
  • Specjalistyczny Gabinet Dermatologiczno-Kosmetyczny
    Kraków, Poland
  • Pratia S,A
    Warsaw, Poland
  • Reumatika- Centrum Reumatologii
    Warsaw, Poland
  • Oddział Kardiologiczny, WSS im. W. Biegańskiego w Łodzi
    Łódź, Poland
  • Polimedica
    Łódź, Poland
  • Clinica Medicală Data Plus SRL
    Bucharest, Sector 1, Romania
  • Institutul Clinic Fundeni
    Bucharest, Sector 2, Romania
  • S.C. Centrul Medical Sana S.R.L.
    Bucharest, Romania
  • S.C. Cardiomed S.R.L.
    Craiova, Romania
  • Institutul de Boli Cardiovasculare Clinica de Cardiologie si Recuperare Cardiovasculara
    Timisoara, Romania
  • Cabinet Medical Medicina Interna
    Timişoara, Romania
  • Institut za kardiovaskularne bolesti Dedinje
    Belgrade, Serbia
  • Institut za reumatologiju
    Belgrade, Serbia
  • Kliničko-bolnički centar "Bežanijska kosa" Klinika za imunologiju i alergologiju
    Belgrade, Serbia
  • Vojnomedicinska akademija Klinika za reumatologiju
    Belgrade, Serbia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in May 2017, 20 months.

Results were first posted in Jun 2019, 2 years 1 month after primary completion.

Of 18 phase 4 interventional studies under Gout, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 20 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2015
First posted
Jul 16, 2015
StartActual
Aug 17, 2015
Primary completionActual
May 10, 2017
CompletionActual
May 10, 2017
Results first posted
Jun 21, 2019
Last update
Jun 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02500641
Responsible party
Sponsor
First posted
Jul 16, 2015
Start date
Aug 17, 2015
Primary completion
May 10, 2017
Completion
May 10, 2017
Results posted
Jun 21, 2019
Last update
Jun 21, 2019

Study contacts

Claudio Borghi, Prof
study director · Policlinico S.Orsola - Malpighi Medicina Interna Borghi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion